Short-term erythropoietin therapy does not increase plasma tissue factor and its inhibitor levels in hemodialysis patients.
Borawski
Jacek
J
Naumnik
Beata
B
Myśliwiec
Michał
M
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D015415:Biomarkers / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology; D015897:Comorbidity; D004730:Endothelium, Vascular / Q000293:injuries; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000097:blood / Q000453:epidemiology / Q000628:therapy; D008074:Lipoproteins / Q000032:analysis*; D011994:Recombinant Proteins; D006435:Renal Dialysis; D013925:Thromboplastin / Q000032:analysis*
D015415:Biomarkers; D001798:Blood Proteins; D008074:Lipoproteins; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D004921:Erythropoietin; D013925:Thromboplastin